Enhancing the Lipid-Lowering Activity of Apigenin through Nanostructured Lipid Carrier (NLC) Modification
DOI:
https://doi.org/10.48048/tis.2026.12054Keywords:
Hyperlipidemia, Apigenin, Nanocarrier, NLC, Release, Cholesterol, Photometric Method, Hyperlipidemia, Apigenin, Nanocarrier, NLC, Release, Cholesterol, Photometric methodAbstract
A total of 2.6 million deaths and 29.7 million Disability-Adjusted Life Years (DALYs) worldwide are caused by hyperlipidemia. Apigenin is known to play a role in cholesterol regulation, but it is limited in terms of solubility and stability. Modification of Nanostructured Lipid Carriers (NLC) is known to increase the bioavailability and effectiveness of hyperlipidemia drugs. This study aims to analyze the potential of NLC drug delivery systems containing apigenin to increase antihyperlipidemia efficacy. Apigenin NLC was formulated using emulsification and melting methods. The formulation was characterized based on particle size, PDI, zeta potential, %EE, and morphology. Subsequently, in vitro release and antihyperlipidemic activity tests were conducted using the photometric method. The apigenin NLC formulation was prepared with a ratio of solid lipid to liquid lipid of 30:70 (F1), 40:60 (F2), and 50:50 (F3). The characterization results showed F3 as the optimal formula with a particle size of 172.30 ± 35.66 nm, polydispersity index of 0.57 ± 0.16, zeta potential of −26.48 ± 0.28 mV, and %EE of 77.8870 ± 0.05%. The NLC modification successfully increased apigenin release by 3-fold compared to unmodified apigenin and the activity of lowering cholesterol levels increased with a decrease in the IC50 value of apigenin’s antihyperlipidemic activity from 132.56 to 101.09 ppm in NLC-Apigenin. This study demonstrates that NLC Apigenin holds promising potential in the treatment of hyperlipidemia.
HIGHLIGHTS
- The best of NLC-Apigenin exhibited nanoscale size (30 ± 35.66 nm), good zeta potential (−26.48 ± 0.28 mV), and high entrapment efficiency (77.8870 ± 0.05%)
- Nanostructured Lipid Carrier (NLC) enhanced apigenin release up to 3-fold compared to unmodified apigenin.
- NLC-Apigenin reduced the IC50 value from 132.56 to 101.09 ppm, confirming improved lipid-lowering activity.
GRAPHICAL ABSTRACT
Downloads
References
N Kullawong, T Apidechkul, P Upala, R Tamornpark, V Keawdounglek, C Wongfu, F Yeemard, S Khunthason and C Chomchoei. Factors associated with elevated low-density lipoprotein cholesterol levels among hill tribe people aged 30 years and over in Thailand: A cross-sectional study. BMC Public Health 2021; 21(1), 498.
HN Pham, R Ibrahim, E Sainbayar, A Olson, A Singh, MY Khanji, J Lee, VK Somers, C Wenger, AA Chahal and MA Mamas. Burden of hyperlipidemia, cardiovascular mortality, and COVID‐19: A retrospective‐cohort analysis of US data. Journal of the American Heart Association 2025; 14(5), e037381.
D Meidayanti. The benefits of lycopene in tomatoes for the prevention of atherosclerosis. Jurnal Medika Hutama 2021; 02(03), 2-6.
S Ramkumar, A Raghunath and S Raghunath. Statin therapy: Review of safety and potential side effects. Acta Cardiologica Sinica 2016; 32(6), 631-639.
MSS Chagas, MD Behrens, CJ Moragas-Tellis, GXM Penedo, AR Silva and CF Gonçalves-de-Albuquerque. Flavonols and flavones as potential anti‐inflammatory, antioxidant, and antibacterial compounds. Oxidative Medicine and Cellular Longevity 2022; 2022(1), 9966750.
D Tang, K Chen, L Huang and J Li. Pharmacokinetic properties and drug interactions of apigenin, a natural flavone. Expert Opinion on Drug Metabolism & Toxicology 2017; 13(3), 323-330.
KK Zhang, W Song, D Li and X Jin. Apigenin in the regulation of cholesterol metabolism and protection of blood vessels. Experimental and Therapeutic Medicine 2017; 13(5), 1719-1724.
J Zhang, D Liu, Y Huang, Y Gao and S Qian. Biopharmaceutics classification and intestinal absorption study of apigenin. International Journal of Pharmaceutics 2012; 436(1-2), 311-317.
O Elkhateeb, MEI Badawy, HG Tohamy, H Abou-Ahmed, M El-Kammar and H Elkhenany. Curcumin-infused nanostructured lipid carriers: A promising strategy for enhancing skin regeneration and combating microbial infection. BMC Veterinary Research 2023; 19(1), 206.
HA Fathi, A Allam, M Elsabahy, G Fetih and M El-Badry. Nanostructured lipid carriers for improved oral delivery and prolonged antihyperlipidemic effect of simvastatin. Colloids Surfaces B Biointerfaces 2018; 162, 236-245.
YC Pyo, P Tran, DH Kim and JS Park. Chitosan-coated nanostructured lipid carriers of fenofibrate with enhanced oral bioavailability and efficacy. Colloids Surfaces B Biointerfaces 2019; 196, 111331.
YO Agrawal, UB Mahajan, VV Agnihotri, MS Nilange, HS Mahajan, C Sharma, S Ojha, CR Patil and SN Goyal. Ezetimibe-loaded nanostructured lipid carrier based formulation ameliorates hyperlipidaemia in an experimental model of high fat diet. Molecules 2021; 26(5), 1485.
C Suhandi, G Wilar, R Lesmana, F Zulhendri, I Suharyani, N Hasan and N Wathoni. Propolis-based nanostructured lipid carriers for α-mangostin delivery: Formulation, characterization, and in vitro antioxidant activity evaluation. Molecules 2023; 28(16), 6057.
X Wang, J Liu, Y Ma, X Cui, C Chen, G Zhu, Y Sun and L Tong. Development of a nanostructured lipid carrier-based drug delivery strategy for apigenin: experimental design based on CCD-RSM and evaluation against NSCLC in vitro. Molecules 2023; 28(18), 6668.
A Firmansya, F Setiawan, L Nurdianti and A Yuliana. Formulation and characterization of buccal film nanoemulsion apigenin as antidiabetic. Indonesian Journal of Pharmaceutical Science and Technology 2022; 1(1), 22-32.
AC Ortiz, O Yañez, E Salas-Huenuleo and JO Morales. Development of an lipid carrier (NLC) by a low-energy method, comparison of release kinetics and molecular dynamics simulation. Pharmaceutics 2021; 13(4), 531.
MME Aldeeb, G Wilar, C Suhandi, AFA Mohammed, A El-Rayyes, KM Elamin and N Wathoni. Formulation and characterization of Sonchus arvensis L. nanosuspension for enhanced antioxidant and lipid-lowering activities. International Journal of Nanomedicine 2025; 20, 5457-5473.
HM Alatawi, SS Alhwiti, KA Alsharif, SS Albalawi, SM Abusaleh, GK Sror and M Qushawy. Nanostructured lipid carriers (NLCs) as effective drug delivery systems: Methods of preparation and their therapeutic applications. Recent Patents on Nanotechnology 2024; 18(2), 179-189.
A Khosa, S Reddi and RN Saha. Nanostructured lipid carriers for site-specific drug delivery. Biomedicine & Pharmacotherapy 2018; 103, 598-613.
D Rahmasari, N Rosita and W Soeratri. Physicochemical characteristics, stability, and irritability of nanostructured lipid carrier system stabilized with different surfactant ratios. Jurnal Farmasi Dan Ilmu Kefarmasian Indonesia 2022; 9(1), 8-16.
S Feng, Z Wang, J Zhao, Z Luo, P Shao, N Xiang and P Sun. Fabrication and characterization of water-soluble phytosterol ester nanodispersion by emulsification-evaporation combined ultrasonic method. Journal of Food Engineering 2020; 276, 109895.
G Jafar, M Abdassah, T Rusdiana and R Khairunisa. Development and characterization of precirol ato 88 base in nanostructured lipid carriers (Nlc) formulation with the probe sonication method. International Journal of Applied Pharmaceutics 2021; 13(3), 43-46.
D Dipahayu and GG Kusumo. Formulation and evaluation of ethanol extract nanoparticles from purple sweet potato leaves (Ipomoea batatas L.) Antin-3 variety. Jurnal Sains Dan Kesehatan 2021; 3(6), 781-785.
L Bonilla-Vidal, M Espina, ML García, L Baldomá, J Badía, JA González, LM Delgado, A Gliszczyńska, EB Souto and E Sánchez-López. Novel nanostructured lipid carriers loading Apigenin for anterior segment ocular pathologies. International Journal of Pharmaceutics 2024; 658, 124222.
RM Shah, DS Eldridge, EA Palombo and IH Harding. Stability mechanisms for microwave- produced solid lipid nanoparticles. Colloids and Surfaces A: Physicochemical and Engineering Aspects 2022; 643, 128774.
CW Lai, FW Low, MF Tai and SB Abdul Hamid. Iron oxide nanoparticles decorated oleic acid for high colloidal stability. Advances in Polymer Technology 2018; 37(6), 1712-1721.
S Bhattacharjee. In relation to the following article ‘DLS and zeta potential - What they are and what they are not?’ Journal of Controlled Release 2016; 235, 337-351.
M Danaei, M Dehghankhold, S Ataei, F Hasanzadeh Davarani, R Javanmard, A Dokhani, S Khorasani and MR Mozafari. Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems. Pharmaceutics 2018; 10(2), 57.
OM Elkhateeb, MEI Badawy, AE Noreldin, HM Abou-Ahmed, MH El-Kammar and HA Elkhenany. Comparative evaluation of propolis nanostructured lipid carriers and its crude extract for antioxidants, antimicrobial activity, and skin regeneration potential. BMC Complementary Medicine and Therapies 2022; 22(1), 256.
L Bonilla-Vidal, M Świtalska, M Espina, J Wietrzyk, ML García, EB Souto, A Gliszczyńska and ES López. Dually active apigenin-loaded nanostructured lipid carriers for cancer treatment. International Journal of Nanomedicine 2023; 18, 6979.
SN Stiani, T Rusdiana and A Subarnas. Improving solubility and dissolution of a natural product apigenin via preparation of solid dispersion by hot melt extrusion. International Journal of Applied Pharmaceutics 2021; 13(3), 47-52.
G Kumar, P Jain, T Virmani, A Sharma, MS Akhtar, SA Aldosari, MF Khan, SOD Duarte and P Fonte. Enhancing therapy with nano-based delivery systems: Exploring the bioactive properties and effects of apigenin. Therapeutic Delivery 2024; 15(9), 717-735.
JE Hyun, HY Yi, GP Hong and JY Chun. Digestion stability of curcumin-loaded nanostructured lipid carrier. LWT 2022; 162, 113474.
P Riangjanapatee and S Okonogi. Effect of surfactant on lycopene-loaded nanostructured lipid carriers. Drug Discoveries & Therapeutics 2012; 6(3), 163-168.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Walailak University
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
